Aim The present systematic review aimed to summarize the available evidence from
published randomized controlled trials (RCTs) regarding the effect of tirzepatide on …

Since the early 2000s, an influx of novel glucose-lowering agents has changed the
therapeutic landscape for treatment of diabetes and diabetes-related complications …

Tirzepatide, a biological entity that acts as an agonist of both the glucose-dependent
insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor …

Background: Tirzepatide (TZP) is a once-weekly glucagon-like peptide 1 (GLP-1) and
glucose-dependent-insulinotropic-polypeptide (GIP) receptor co-agonist approved for T2D …

Atherosclerotic cardiovascular disease (ASCVD) is a major cause of morbidity and mortality
in both men and women with T1DM and T2DM. In patients with T1DM, intensive glycemic …

Diabetes leads to a significantly accelerated incidence of various related macrovascular
complications, including peripheral vascular disease and cardiovascular disease (the most …

Die letzten Jahre markieren eine Revolution im Bereich der pharmakologischen Ansätze zur
Adipositastherapie als direkte Antwort auf die weltweit zunehmende Prävalenz von …

Objective: To assess the rate of gastric emptying in spontaneously hypertensive rats (SHR)
and to evaluate rapid gastric emptying as a possible predisposing factor for hypertension …

Metabolic syndrome is characterized by the accumulation of adverse cardio-metabolic risk
factors. Non-pharmacological measures are an important part of its treatment, but many …

Tirzepatide is a novel dual gastric inhibitory polypeptide (GIP)/glucagon-like peptide-1 (GLP-
1) receptor co-agonist recently approved for the treatment of type 2 diabetes (T2D) and …